[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365944-105":59,"doc-detail-365944-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","pan-cancer-analysis-of-tmed2-unraveling-potential-immune-characteristics-and-prognostic-value-in-cancer-therapy","Pan-cancer analysis of TMED2 - unraveling potential immune characteristics and prognostic value in cancer therapy","","Pan-cancer analysis identifies transmembrane emp24 domain-containing protein 2 (TMED2) as a regulator potentially linked to tumorigenesis, while its pan-cancer signaling roles and immune associations remain insufficiently clarified. The study integrates multiple public databases to evaluate prognosis, mutations, pathway enrichment, and single-cell immune characteristics, alongside immune infiltration, checkpoint patterns, and co-expressed PPI networks. Cellular validation further examines TMED2 functions at the cellular level. Results indicate differential TMED2 expression, immune correlations, and pro-malignant effects in glioma cells, supporting TMED2-targeted immunotherapy strategies.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pan-cancer-analysis-of-tmed2-unraveling-potential-immune-characteristics-and-prognostic-value-in-cancer-therapy/365944/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pan-cancer-analysis-of-tmed2-unraveling-potential-immune-characteristics-and-prognostic-value-in-cancer-therapy/365944.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn Holloway","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-17","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What is TMED2 and why is it studied in pan-cancer research?","Question",{"text":113,"@type":114},"TMED2 is involved in protein sorting and transport between the Golgi apparatus and the endoplasmic reticulum. The study investigates its regulatory role in tumorigenesis and its potential connections to immune mechanisms across cancers.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was TMED2 analyzed across cancer types in this work?",{"text":118,"@type":114},"The study performs comprehensive pan-cancer analysis using multiple public databases, including assessments of prognostic significance, gene mutations, pathway enrichment, single-cell sequencing, immune characteristics, co-expressed PPI networks, and treatment response to immunotherapy and small molecules.",{"name":120,"@type":111,"acceptedAnswer":121},"What major findings link TMED2 to immune features and prognosis?",{"text":122,"@type":114},"TMED2 mRNA differs between cancerous and normal tissues and correlates with prognosis in several cancers. It shows associations with immune infiltration and immune checkpoints, and pathway enrichment highlights processes such as cell cycle and PI3K/Akt signaling.",{"name":124,"@type":111,"acceptedAnswer":125},"Does TMED2 influence cancer cell behavior in experimental validation?",{"text":126,"@type":114},"Cellular studies indicate that TMED2 expression promotes glioma cell growth, migration, and invasion, supporting its potential functional role beyond computational correlations.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},365944,1790379144,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":36,"preview_page_count":19,"preview_urls":150},2336474466712,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","TYPE Original Research PUBLISHED 30 May 2025  \nDOI 10.3389/fimmu.2025.1578627  \nOPEN ACCESS  \nEDITED BY  \nRiccardo Dolcetti,  \nPeter MacCallum Cancer Centre, Australia  \nREVIEWED BY  \nShuzhao Chen,  \nFirst Afﬁliated Hospital of Shantou University Medical College, China  \nAnnarita Nappi,  \nUniversity of Naples Federico II, Italy  \n*CORRESPONDENCE  \nYuchao Gu  \n [guych@126.com](guych@126.com)[ ](guych@126.com)Xiao Wu  \n[wuxiao457891@outlook.com](wuxiao457891@outlook.com)[ ](wuxiao457891@outlook.com)Changning Sun  \n [scn199574@outlook.com](scn199574@outlook.com)  \n†These authors have contributed equally to this work  \nRECEIVED 18 February 2025  \nACCEPTED 19 May 2025  \nPUBLISHED 30 May 2025  \nCITATION  \nWang Z, Sun C, Wang P, Lin S, Wu X and Gu Y (2025) Pan-cancer analysis of TMED2:  \nunraveling potential immune characteristics and prognostic value in cancer therapy. Front. Immunol. 16:1578627 .  \ndoi: 10.3389/fimmu.2025.1578627  \nCOPYRIGHT  \n© 2025 Wang, Sun, Wang, Lin, Wu and Gu.  \nThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nPan-cancer analysis of TMED2: unraveling potential immune characteristics and prognostic value in cancer therapy  \nZhuangzhi Wang 1,2†, Changning Sun 1*†, Pengfei Wang 3, Shouyang Lin 1,2, Xiao Wu 3* and Yuchao Gu 1*  \n1Qingdao Center of Technology Innovation for Shark Antibody Development, College of Biological Engineering, Qingdao University of Science and Technology, Qingdao, China, 2School of Medicine and Pharmacy, Ocean University of China, Qingdao, China, 3 Department of Respiratory and Critical Care Medicine, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China  \nBackground: Transmembrane emp24 domain-containing protein 2 (TMED2) is involved in the sorting and transport of proteins between the Golgi apparatus and the endoplasmic reticulum. Recent research has identiﬁed a close association between TMED2 and tumorigenesis, yet its regulatory role and underlying mechanisms in pan-cancer signaling pathways remain unexplored.  \nMethods: We conducted a comprehensive pan-cancer analysis of TMED2 using multiple public databases. These analyses included assessments of prognostic signiﬁcance, gene mutations, pathway enrichment, single-cell sequencing analysis, immune characteristics, co-expressed gene PPI network analysis, as well as the therapeutic response of TMED2 in immunotherapy and small molecule sensitivity. Finally, we examined the role that TMED2 plays at the cellular level.  \nResults: Our results show that the mRNA levels ofTMED2 differ signiﬁcantly between cancerous and normal tissues and are closely associated with cancer prognosis. Speciﬁcally, in CESC, MESO, LGG, and UVM, overexpression of TMED2 correlates with patient prognosis and various clinical pathological features. TMED2 is signiﬁcantly associated with immune inﬁltration (including endothelial cells, neutrophils, dendritic cells, and eosinophils), immune checkpoints (CD274, HAVCR2, PDCD1LG2, and SIGLEC15), and signaling pathways (cell cycle and PI3K/ Akt) . Single-cell sequencing reveals that TMED2 is predominantly expressed in tumor cells of cervical cancer, glioma, and mesothelioma. Enrichment analysis shows that genes co-expressed with TMED2 are primarily involved in processes like endoplasmic reticulum stress and the ERAD pathway. Furthermore, cellular studies indicated that TMED2 expression promotes the growth, migration and invasion of glioma cells.  \nConclusion: Our integrated analysis suggests that targeting TMED2, along with its associated genes and signaling pathways, could represent a new str","cbCaim0IjblrGCfg","https://ap.wps.com/l/cbCaim0IjblrGCfg","pdf",26795688,16,"English","# Background\n## Immunotherapy and cancer heterogeneity\n## TMED2 function and rationale\n# Methods\n## Pan-cancer database integration\n## Prognostic, mutation, enrichment, and immune analyses\n## Single-cell and PPI/therapeutic response assessments\n## Cellular level investigation\n# Results\n## Differential expression and prognosis association\n## Immune infiltration and immune checkpoints\n## Pathway enrichment and single-cell expression patterns\n## Cellular effects on glioma\n# Conclusion\n## TMED2 targeting as an immune treatment strategy","[{\"question\":\"What is TMED2 and why is it studied in pan-cancer research?\",\"answer\":\"TMED2 is involved in protein sorting and transport between the Golgi apparatus and the endoplasmic reticulum. The study investigates its regulatory role in tumorigenesis and its potential connections to immune mechanisms across cancers.\"},{\"question\":\"How was TMED2 analyzed across cancer types in this work?\",\"answer\":\"The study performs comprehensive pan-cancer analysis using multiple public databases, including assessments of prognostic significance, gene mutations, pathway enrichment, single-cell sequencing, immune characteristics, co-expressed PPI networks, and treatment response to immunotherapy and small molecules.\"},{\"question\":\"What major findings link TMED2 to immune features and prognosis?\",\"answer\":\"TMED2 mRNA differs between cancerous and normal tissues and correlates with prognosis in several cancers. It shows associations with immune infiltration and immune checkpoints, and pathway enrichment highlights processes such as cell cycle and PI3K/Akt signaling.\"},{\"question\":\"Does TMED2 influence cancer cell behavior in experimental validation?\",\"answer\":\"Cellular studies indicate that TMED2 expression promotes glioma cell growth, migration, and invasion, supporting its potential functional role beyond computational correlations.\"}]","Pan-cancer analysis of TMED2 - unraveling potential immune characteristics and prognostic value in cancer therapy | PDF",1790163072,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a8e285b1e48ea7be4cce0d7a69df002.webp",983,1389,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad3d827f31bffdfe81d3cdffac19ab56.webp",982,1388,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/000ff0b79fc40149eb5a0e6d249c1aad.webp",981,1386,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90770834446b1af084667ec42c6a2b3c.webp",980,1385]